• Participants who completed the 48-week treatment period of Study DRI16762 or ACT18301, including the EOT visit, as per protocol

• Participants with stable background therapy with moderate or high-dose ICS in combination with the following controller medications, as maintained during the respective parent study in which they have participated:

‣ For Study DRI16762: At least 1 and no more than 2 additional controllers (eg, LABA, LAMA, LTRA, or methylxanthines) with or without oral prednisone

⁃ For Study ACT18301: LABA with or without LTRA

• Participants who are able and willing to participate in the open-label extension study, and to comply with requested study visits and procedures

• Contraception for male and female participants

• For female participants:

⁃ must agree to use contraception/barrier

⁃ not pregnant or breast feeding

⁃ no eggs donation or cryopreserving eggs

• For male participants:

⁃ No sperm donation or cryopreserving sperm

• Capable of giving signed informed consent